Even though there are several biosimilars for the best-selling drug in the world, Humira, and they've been on the market in the European Union since 2018, American patients must wait another two years for them to be available here due to the manufacturer's aggressive patent thicket strategy of overlapping and late-filed patents.
Discussing delays in biosimilar availability due to patent strategies.
Share
More from Susan Collins
These allegations are appalling. Nevertheless, it is not up to me to choose the Democratic nominee for Senate.
the fact remains that there are must-pay bills and urgent requirements facing the department that affect the ability of our troops to be well trained and more broadly of the U.S. military to deter and defend against potential aggressors…
Obviously, I’m disappointed in that decision, which turned abortion issues back to the states.
Other voices in this conversation
